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Abstract

Background: Available literature suggests that provider adherence to best practice
guidelines regarding the prescribing and management of opioid therapies is low.
Documentation of patient screening for present or future opioid use disorder is
inconsistent. Provider incorporation of evidence-based guidelines into routine patient care
is essential to optimizing outcomes related to opioid use disorders.
Purpose/Specific Aims: The purpose of this scholarly project was to facilitate
recognition of patients at high risk for opioid use disorders and facilitate best evidencebased practices in the care of this population. Specific aims were to achieve provider
compliance with: patient risk screening, PDMP review, completion of signed care plans,
and reduction of inappropriate opioid prescriptions.
Methods: A quasi-experimental design was used for this quality improvement project.
The sample included patients receiving treatment for acute or chronic pain, or who were
identified as having a substance use disorder. The project was conducted at an internal
medicine practice in the northeast region. The intervention included an educational
program addressing the ASAM guidelines and ORT utilization with implementation of a
SmartPhrase in Epic. Baseline data was collected for the two-month period preceding the
intervention and post-intervention data was collected for the three-month period
following the intervention. Differences in pre- and post- intervention results were
analyzed using chi square.
Results: This project resulted in improved compliance with the implementation of urine
toxicology screening, PDMP review, and completion of a controlled substance
agreement. Compliance with ORT was not achieved.
Conclusion: This project led to an increase in compliance with best opioid prescribing
practices. The ORT was not consistently implemented; however, the number of new
opioid prescriptions remained negligible. Additional efforts will be necessary to maintain
the progress achieved in this project including attention to continued provider education.
Real-time auditing and feedback will also be incorporated, and opportunities to involve
office staff will be explored.
Key Words: Opioid Use Disorder; Opioid Risk Tool; Evidence-Based Practice
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IMPROVING COMPLIANCE WITH BEST PRACTICE STANDARDS FOR
PATIENTS AT RISK FOR OPIOID USE DISORDER
The prevalence of opioid use disorder (OUD) and subsequent related overdose
rates have increased significantly over the last decade, resulting in considerable morbidity
and mortality (Strain, 2018). Identification and implementation of strategies to mitigate
the negative outcomes associated with OUD is essential. This scholarly project was
designed to translate evidence-based guidelines on opioid prescribing into practice and to
evaluate the effectiveness of the intervention on related processes and outcomes.
Background and Significance
Opioid use disorder is defined by the Center for Disease Control (CDC) as a
problematic pattern of opioid use leading to clinically significant impairment (2018).
Opioid use disorder has become a topic of national interest in the past decade, with
aggressive reforms having been made to federal and state prescribing regulations. In the
United States, there is an estimated incidence of opioid use disorder of two to sixteen
million people (Barclay, Owens, & Blackhall, 2014; Reyes-Gibby, Anderson, & Todd,
2010; Shuckit, 2016; Wei, et al., 2019). Over four million people have reported nonmedical use of prescription opioids in their lifetime (Rager & Schwartz, 2017; Schuckit,
2016). Nearly half of patients who report the recreational use of opioids meet the criteria
for a diagnosis of opioid use disorder based on the criteria according to the Diagnostic
and Statistical Manual – Fifth Edition (DSM-V) (Rager & Schwartz, 2017; Shuckit,
2016; Strain, 2018). According to the CDC (2018), opioid use disorder begins with a
prescription medication in 62% of cases. These opioids are either prescribed for the
individual or taken from a relative or friend (CDC, 2018; Rager & Schwartz, 2017).
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Many patients who begin misusing prescription opioids later shift to illicit opioids, such
as heroin, which is associated with a higher risk for overdose (Strain, 2018). Heroin is
often mixed with the synthetic opioid, Fentanyl, which significantly increases the risk of
overdose and mortality (NIDA, 2019).
To address the epidemic of opioid use disorder, the National Academies of
Sciences, Engineering and Medicine released the seminal report Pain Management and
the Opioid Epidemic: Balancing Societal and Individual Benefits and Risks of
Prescription Opioid Use (Bonnie, Ford, & Phillips, 2017). This report identified the need
for broad intervention across various levels. Specifically, the report calls for the need to
restrict supply, optimize prescribing practices, reduce demand, and reduce harm (Bonnie,
et al., 2017). Optimization of prescribing practices is a primary responsibility of
providers with authority to prescribe opioid medications.
Evidence-based guidelines supporting best practices in opioid prescribing include
patient screening for risk of opioid use disorder using a valid screening tool and provider
implementation of a controlled substance agreement, review of the prescription drug
monitoring program (PDMP), and monitoring of urine toxicology results for nonprescribed substances for all patients receiving opioid medications (ASAM, 2015).
Despite the development of national guidelines, provider compliance with these best
practices is low, and data describing the effectiveness of interventions to achieve
compliance with these best practices is limited (Naimer, Munro, Singh, & Permaul,
2019). Therefore, there is a need for new evidence to support best practices in the
implementation of evidence-based best practices in opioid prescribing.
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Literature Review
Opioid Use Disorder and Opioid Misuse
Opioid use disorder is a chronic relapsing condition that often occurs when an
individual develops dependence on these medications. Opioids activate mu receptors,
initiating intracellular communication by G protein stimulation (Strain, 2018). These
receptors are present in the central and peripheral nervous system, with the stimulation of
either causing different effects on the body. For example, central nervous system mu
receptor stimulation results in physiologic responses such as respiratory depression,
analgesia, euphoria, and miosis (Strain, 2018). Stimulation of the receptors within the
peripheral nervous system results in physiologic responses such as cough suppression and
opioid-induced constipation (Strain, 2018). Activation of both central and peripheral mu
receptors may result in negative or positive effects, but adverse effects become more
common with overuse.
The DSM-V defines opioid use disorder as a problematic pattern of opioid use
that leads to clinically significant impairment or distress (American Psychiatric
Association, 2016). To meet diagnostic criteria for opioid use disorder, a patient must
have at least two of the following characteristics: opioids taken in larger amounts than
intended, persistent desire or unsuccessful attempts to reduce use, increased time spent
attempting to obtain the substance, the development of cravings when the substance is not
obtained, use leading to failures in work or home life, continued use despite clear social
and interpersonal problems, and signs of tolerance or withdrawal without constant use
(APA, 2016). The severity of the disease is based on how many of the above conditions
are met.
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With continued use of the substance, tolerance may occur. As tolerance occurs,
the patient becomes less responsive to the effects of the medication, eventually requiring
a larger dose to achieve the same effect previously achieved with smaller doses (Strain,
2018). The addictive nature of these medications may also lead to withdrawal symptoms
when the medication is stopped. These include tearing eyes, rhinorrhea, yawning, muscle
twitching, and hyperactive bowel sounds, cravings, and dysphoria (Strain, 2018). Opioid
withdrawal symptoms are measured by healthcare clinicians using the Clinical Opiate
Withdrawal Scale (COWS), which classifies severity of symptoms based on clinical
presentation and self-reported symptoms (ASAM, 2015). The desire to avoid a state of
withdrawal often leads to continued escalating use, which puts patients at highest risk for
overdose.
The overall rate of OUD is estimated to be between two to sixteen million
Americans (Chen, Hom, Richman, Asch, Podchiyska, & Johansen, 2016; Florence, Luo,
Xu, & Zhou, 2016; Bonnie, Ford, & Phillips, 2017). The estimated prevalence of OUD
among patients who were prescribed an opioid is 8%, and the estimated incidence of
combined misuse, OUD and aberrant behaviors ranges from 15-26% (Bonnie, et al.,
2017). The incidence of OUD among patients prescribed opioids for chronic pain is even
higher at 21-29% (Vowles, McEntee, Julnes, Frohe, Ney, & van der Goes, 2015). Not
only is the problem of OUD far reaching, but the incidence has continued to increase. In
fact, Florence, et al., (2016), report that the incidence of OUD has increased by 200,000
individuals since 2007.
Opioid use disorder carries a significant cost burden. The cost associated with the
care of patients with OUD was found to be $13,000-$17,000 higher compared to patients
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without an opioid use disorder (Florence, Luo, Xu, & Zhou, 2016). These authors further
estimated the aggregate cost of OUD to be between $70-$80 billion (Florence, et al.,
2016).
Screening Tools
As opioid use disorders are becoming more prevalent, screening tools are being
developed to identify risk among populations of all ages, genders, and risk factors. These
screening tools are imperative in better understanding aberrant drug-related behaviors to
assist providers in recognizing early signs of addiction and referring to appropriate care
centers (Moore, Jones, Browder, Daffron, and Passik, 2009). There is not currently one
universal screening tool intended for use across all patient populations. There are,
however, recommendations in place from the CDC and the American Society of
Addiction Medicine (ASAM) that encourage clinicians to use at least one of the
screening tools available to assess for opioid use and related risk in the general
population. Most primary care offices for adult patient populations have incorporated
screening tools into their initial assessment of the patient and continue to assess
throughout their care length. If patients are identified as currently having, or as being at
high risk for developing an opioid use disorder, clinicians are encouraged to implement
evidence-based interventions as appropriate for each case. Examples of commonly
utilized screening tools include the Screener and Opioid Assessment for Patients with
Pain (SOAPP), the Opioid Risk Tool (ORT), and the Diagnosis, Intrac (NIDA, 2018).
These screening tools vary in utilization based on patient population of each clinical site.
One study performed by Moore, Jones, Browder, Daffron, and Passik, (2009),
demonstrated that the SOAPP performed the best of the three screening tools with credit
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given to its utility and specificity. The second best validated tool was the ORT score,
with increased feasibility found in clinical settings (Moore, et al., 2009). Barclay, Owens
and Blackhall (2014) utilized the ORT in their clinical practice due to its high sensitivity
and specificity, especially with the combined assessment of results through clinical
examination. They also noted that the ORT is the only screening tool to focus on family
history and personal history of substance use (Barclay, et al., 2014). Overall, there is not
one tool recommended over another and further research is required to standardize
screening procedures.
The ORT has been recommended by the Rhode Island Department of Health as a
best practice measure for screening patients for opioid use disorders. The ORT is well
validated, and is more feasible for use in the proposed study settings due to ease of
administration and minimal time requirements for implementation. For these reasons, the
ORT has been selected as the screening tool for this study.
The ORT is a clinician or self-reported screening tool designed to assess adults,
particularly in the primary care setting, for the potential abuse of prescribed opioid
medications for acute or chronic pain. This tool should be administered before initiation
of opioid therapy to determine future risk of opioid disordered behavior. The tool assigns
point values differentiated by gender for family history of substance abuse, personal
history of substance abuse, age group, history of preadolescent sexual abuse, and
psychological disease presence. Higher scores are correlated with higher risk of
disordered medication behavior and should alert the clinician that the abuse potential is
high. The use of the ORT in clinical practice is intended to help clinicians weigh potential
risks and benefits of initiation of opioids (NIDA, 2018).
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The ORT score was validated using a c-statistic, in which sensitivity and
specificity are measured simultaneously. The c-statistic measures predictive ability of a
prognostic model and, specifically for the ORT score, it is defined as the likelihood that a
patient who exhibits an aberrant behavior will have a higher predicted risk of such a
behavior than does a patient who does not exhibit such an aberrant behavior (Webster &
Webster, 2006). C-statistics are interpreted as c = 0.5 suggesting no discrimination, 0.7 <
c <0.8 is considered acceptable discrimination, 0.8 < c < 0.9 is considered excellent
discrimination, and c >0.9 is considered outstanding discrimination (Webster & Webster,
2006). The study found that the female prognostic model had a c statistic of 0.85 and the
male model had a c statistic of 0.82 (Webster & Webster, 2006). These indicate the
models had excellent discrimination and therefore, excellent validity when utilized in the
clinical setting.
Addressing the Epidemic
In addition to utilizing a screening tool, other best practice requirements for
providers include reviewing the Prescription Drug Monitoring Program (PDMP) in the
state of residence prior to initiating an opioid prescription, performing random urine
toxicology screening on patients receiving controlled substances to evaluate for
compliance with prescribed therapy and abstinence from substances that are not
prescribed, and ensuring that there is a provider-patient controlled substance agreement in
place for those patients receiving opioid prescriptions that explicitly describes the
expectations of both parties (provider and patient) with regards to compliance with the
treatment plan (CDC, 2019; RIDOH, 2020).
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Multiple authors describe success with PDMP utilization in clinical practice.
Total opioid prescriptions decreased with consistent provider monitoring of the PDMP in
cases where patients were using or being considered for an opioid prescription (Rasubala,
Pernapati, Velasquez, Burk, & Ren, 2015; Ringwalt, Schiro, Shanahan, Proescholdbell,
Meder, Austin, & Sachdeva, 2015). In addition, states using PDMP in their practices
reported a smaller increase in opioid treatment admissions and lower mortality rates
overall (Reisman, Shenoy, Atherly, & Flowers, 2009). Urine toxicology screens are also
positively associated with compliance with prescribed substances and avoidance of nonprescribed substances (Blum, Han, Femino, Smith, Saunders, Simpatico, Schoenthaler,
Oscar-Berman, Gold, 2014). In this study, patients were found to be 12% more compliant
with prescribed substances than baseline data one year earlier with the addition of urine
toxicology screens (Blum, et al., 2014).
Current guidelines set forth by the CDC and RIDOH may have limitations in
predicting opioid use disorder or opioid overdose risk, and may have limited
effectiveness in improving outcomes. Wei, Chen, Fillingim, Schmidt, and Winterstein
(2019) posit that over 35% of commercially insured patients with OUD or opioid
overdose had no opioid prescriptions filled within the last year per the PDMP, and those
who did have opioid prescriptions filled were at a morphine milliequivalent lower than
the CDC recommendation. In addition, not all states participate in the PDMP and
information may not accurately cross state borders of those states who do (Griggs,
Weiner, & Feldman, 2015). Griggs, Weiner, and Feldman (2015) also state that patients
with fragmented care or undertreated care may have falsely assumed “suspicious”
PDMPs, which may impact care received in a new office.
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Colleen (2009) and Yarbrough (2018) challenged the effectiveness of a patientprovider controlled substance agreement, noting that it may imply distrust of the provider
and undermine the therapeutic relationship. Rager and Schwartz (2017) also challenge
that a CSA may not be ethical if the patient is asked to sign whether while in pain or in an
attempt to gain controlled medications. These authors note that “their consent has
questionable legal and moral status” (Rager & Schwartz, 2017, p. 24).
In addition, Collen (2009) noted that urine toxicology screening has low utility in
the clinical setting. There is a large margin for error related to improper collection,
transportation, and resulting of these tests, rendering them incorrect and ineffective for
proper controlled therapy monitoring (Collen, 2009). Confirmatory testing, in which
urines are sent out to a lab, takes almost one week to result, is more expensive to
complete, and still often leads to false negative or positive results. Misinterpretations of
these tests can lead to devastating outcomes for the patient, and patient-provider
relationship.
Despite the above limitations, interventions such as the CSA, PDMP, and urine
toxicology screening have shown modest to low improvements in outcomes (Bonnie,
Ford, & Phillips, 2017; Yarbrough, C., 2018). Overall, evidence around these
interventions is positive, and they are currently considered the best practice under current
national and local guidelines. Further research is needed to better establish the
effectiveness of these interventions, and to continue to identify new practices that may
lead to improved outcomes.
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Evaluating Effectiveness of Guidelines
Limited evidence describing the effectiveness of implementation strategies to
translate evidence-based opioid prescribing and monitoring practices was found in the
literature. Many providers lack confidence with opioid prescribing and report inadequate
education related to the topic (Naimer, et al., 2019; Wei, et al., 2019). Specifically,
academic family medicine teaching centers face challenges when it comes to opioid
prescribing, including higher rates of opioid misuse in the resident patient population and
lower levels of resident confidence and experience managing chronic non-cancer related
pain (Naimer, et al., 2019).
Several published quality improvement studies have demonstrated the successful
implementation of evidence-based opioid prescribing guidelines into practice. One
prominent study performed in 2016 implemented guidelines into primary care clinics via
in person and electronic education. Pre-intervention data was obtained through chart
review for patients receiving more than three opioid prescriptions. After guidelines were
introduced, patient charts were retrospectively reviewed during the post-intervention
period. Researchers found that patients receiving acute or chronic opioid prescriptions
decreased (p = 0.02, p = 0.03), while urine toxicology screenings increased (p = 0.005)
(Chen, Hom, Richman, Richman, Asch, Podchiyska, & Johansen, 2016).
Naimer, Munro, Singh, and Permaul (2019) implemented and evaluated the
HeLP, or “Healthy Living with Pain”, initiative aimed at improving family medicine
resident opioid prescribing practices. Six core components were identified, to include a
collaborative practice model, patient registry formation, resident education, clinical
decision supports, faculty supervisors, and patient record reviews (Naimer, et al., 2019).
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Implementation of these aspects into the clinical practice setting led to better resident
adherence to national practice guidelines and safer opioid prescribing (Naimer, et al.,
2019). This article was one of the first to demonstrate specific outcome measures related
to resident prescribing practices. The authors call for further research demonstrating the
ability to adapt and scale the model to other practice settings.
Organizational Assessment/Local Problem
Local Problem
Data collected by the National Institute on Drug Abuse reveals that there were
277 opioid-related overdose deaths in Rhode Island in 2017, with an adjusted rate of 26.9
deaths per 100,000 persons (NIDA, 2019). This is significantly higher than the national
average in 2017, of 14.6 per 100,000 persons (NIDA, 2019). Deaths specifically
involving fentanyl rose from 12 reported associated deaths in 2012 to 201 deaths in 2017
in Rhode Island alone (NIDA, 2019), with a reported 28,466 patient deaths related to
fentanyl throughout the United States (NIDA, 2019). While Rhode Island providers were
below the national average for opioid prescriptions, at 51.2 per 100 persons and 58.7 per
100 persons respectively, the ability to legally or illegally obtain opioids for Rhode Island
residents increased tremendously (NIDA, 2019). This increase is connected to significant
morbidity and mortality, demonstrated by rising overdose-related death rates. In addition,
co-occurring disease rates are increasing as well. Specifically, 9% of the 40,000 new HIV
diagnoses in the United States were attributed to intravenous (IV) synthetic opioid drug
use (NIDA, 2019). In Rhode Island, 70 new cases of HIV occurred in 2017, with 11.8%
male attribution to IV drug use, and 21.1% of female attribution to IV drug use (NIDA,
2019). Hepatitis C rates are also rising. In 2016, there was an estimated 41,200 new
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national cases of acute Hepatitis C with 68.6% of these attributed to intravenous (IV)
drug use (NIDA, 2019). In Rhode Island, there was an estimated 10,100 persons living
with Hepatitis C in 2016, but specific data related to IV drug use was unavailable due to
lack of reporting (NIDA, 2019).
In response to this upward trend in opioid-related deaths, the Rhode Island State
Governor, Gina Raimondo, initiated a program in 2016 named the “Governor’s Task
Force.” This taskforce is a committee established to reduce overdose deaths in Rhode
Island by utilizing multiple techniques towards a goal of reducing opioid-related deaths
by one third in three years (Prevent Overdose RI, 2019). The action plan associated with
this committee involves four major components including prevention, rescue, treatment,
and recovery.
To address the taskforce’s action plan, the Rhode Island Department of Health
(RIDOH) put forth guidelines for providers to follow when prescribing an opioid. These
guidelines are in alignment with those set forth by the American Society of Addiction
Medicine (ASAM), which aim to support evidence-based prescribing practices (RIDOH,
2019). The RIDOH recommends completing a full medical history and physical
examination on each patient, including assessment of pain characteristics, physical and
psychological functioning, personal and family history of substance abuse, coexisting
conditions, and determination of the indication for the use of a controlled substance
(RIDOH, 2019). According to these guidelines, patients should be screened annually to
assess for the presence of substance abuse. Individuals demonstrating current substance
abuse should be referred to treatment. Prior to prescribing opioid medications, the
provider should discuss the risks of opioid medications and a create a treatment plan
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balancing risks and expected benefits. This plan should be implemented in the form of a
controlled substance agreement that is signed by both the provider and patient. Once an
opioid prescription is determined to be necessary, the provider should have the patient
sign an informed consent form, review the prescription drug monitoring program
(PDMP), co-prescribe naloxone, and frequently reassess the patient for the continued
need for opioids (RIDOH, 2019).
Prior to the implementation of this project, the practice setting did not routinely
use screening methods for opioid use disorders, and implementation of PDMP checks,
urine toxicology testing, and patient contracts was inconsistent. Improving compliance
with these best practice measures is essential to optimizing outcomes related to OUD.
Organizational Assessment
An analysis was completed prior to the implementation of the project to identify
potential strengths, weaknesses, opportunities and threats (SWOT). Strengths of the
project relate to the internal factors that would benefit the project and contribute to its
success. Strengths identified in this project included the availability of the intended
patient population, with a majority of patients at the clinical site seeking care for pain
management or substance use needs. Providers in the practice setting were easily engaged
in the project, and there was strong support for the implementation of best practice for
minimizing OUD among administrators at the organizational level. Given the limited
compliance with best practice recommendations and the lack of current improvement
initiatives related to this problem, there was a strong need for this project. Providers at
the practice setting were already familiar with the use of evidence-based practice
protocols and assessment tools used for other populations. Provider familiarity with the
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use of such protocols facilitated the implementation of the RIDOH guidelines and ORT
assessment. In addition, due to increasing national attention to the opioid epidemic, the
public is increasingly aware of risks associated with opioid use, potentially increasing
their willingness to follow prescriber recommendations.
Weaknesses refer to the internal factors that threaten the success of the project.
Although engagement among administrators and providers was generally high, the
potential for decreased administrative or provider engagement at any of the clinical sites
was a risk. More specifically, there was a risk that providers may be resistant to changes
in current practice or may view the time required for participating in the education
sessions as either a distraction or loss of billable hours. Providers may have also felt that
their discretion regarding the use of opioid prescriptions for patients with pain
management needs was in question. In addition, staff turnover presented another
challenge, with residents routinely rotating through the practice setting. To minimize the
impact of turnover, the intervention was completed between resident rotation changes.
Opportunities are defined as external factors that increase social engagement in the
project. Related to this project, a strong national public health initiative to reduce illicit
opioid use and subsequent overdose risk was a major leverage point. At the state level,
the RIDOH initiatives and creation of the Governor’s Task Force has significantly
increased the amount of public awareness given to the topic of opioid use and overdoserelated deaths. It was thought that the presence of positive local and national attention
would increase patient confidence in provider decision-making and the need for the
proposed interventions.
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Threats are described as external factors that may challenge the project goals. A
major threat to this project included the presence of advocacy groups that have been
forming to vocalize the need for increased pain management. These groups feel that
restrictions on opioid prescribing are detrimental to the management of pain. Increasing
resistance among groups opposed to the implementation of evidence-based opioid
prescribing practices may contribute to provider fear of potential lawsuits or negative
publicity regarding the provider or facility, thereby undermining project goals.
Problem Statement and Study Question
Currently available evidence suggests that provider adherence to best practices is low
(ASAM, 2015; Naimer, et al., 2019). As the numbers of patients with opioid use disorder
and subsequent overdoses rise, it is imperative that providers incorporate evidence-based
prescribing and patient management practices into their practice. Optimizing outcomes
related to opioid use disorders depends on the consistent implementation of best practices
by providers in all care settings.
Purpose Statement and Specific Aims

The purpose of this project was to facilitate recognition of patients at high risk for
opioid use disorders and facilitate best evidence-based practice in the care of this
population. The specific aims were to achieve provider compliance with the
implementation of best practice guidelines including
1. Opioid risk screening via ORT
2. Implementation of PDMP review, signed care plans, and urine toxicology
screening and,
3. Reducing inappropriate opioid prescriptions.
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Conceptual/Theoretical Framework
Kurt Lewin’s Change Theory was developed in 1940 and identifies three distinct
stages of behavior change (Petiprin, 2016). The Change Theory involves the concepts of
driving forces, restraining forces, and equilibrium that relate to the change in behavior
stages. Driving forces are those that push one in the direction of change, allowing
acceptance of the change that will occur. Restraining forces, conversely, are those that
hinder or oppose the change. Equilibrium is a state of being where driving forces are
equal to restraining forces. When driving and restraining forces are in equilibrium driving
forces are unable to overcome restraining forces, therefore, change will not occur. To
lead change, the key forces related to the desired change are identified and manipulated
so that driving forces are increased over restraining forces (Petiprin, 2016).
In regards to the proposed project, an initial assessment was employed to identify
outdated or ineffective prescribing and assessment techniques with co-identification of
driving and restraining forces for the adoption of new techniques. Change was facilitated
by minimizing restraining forces and working to ensure that the reason for the intended
change was perceived as beneficial to the participants. Work to establish refreezing is
ongoing and will occur when the intervention becomes part of standardized practice and
best practice adoption is identified in all appropriate clinical situations. Appendix C
demonstrates the forcefield analysis for this project.
Another framework used to support this project was the middle range theory, the
Theory of Pain: A Balance between Analgesia and Side Effects (Good, 2013). This
theory describes the balance between efforts to increase patient satisfaction with relief
from pain with ensuring minimal, or absence of, side effects (Good, 2013).
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Pharmacologic measures to alleviate pain may include opioid or non-opioid pain
medications, while non-pharmacologic pain measures may include any adjunct therapies
known to alleviate pain or suffering, such as massage, imagery, music, or relaxation
techniques (Good, 2013). The provider is required to perform adequate and regular
assessments of pain and side effects at particular intervals with a mutually agreed-upon
goal in mind. If the number and intensity of adverse effects are unacceptable to either
party, the therapy is discontinued. The absence of reported adverse effects would be an
ideal outcome for the patient and provider. Adverse effects from therapies may include a
variety of unpleasant occurrences, ranging from acute gastrointestinal distress to the
development of an addiction to a prescribed substance. Patient education is an important
aspect of the theory and provides encouragement and instruction regarding expectations,
actions, and mutually agreed upon, safe goals for relief (Good, 2013).
This theory may be applied to patients receiving chronic or acute opioid therapy
in a primary care office setting for any number of conditions, as it addresses the complex
balance of risks and benefits associated with high-risk medications. Patients experiencing
pain seek relief, and practitioners treat pain with a variety of therapies with the intention
of providing a reduction in pain and improvement in quality of life. If a provider feels an
opioid prescription is a necessary component of the treatment plan, consistent evaluation
of medication efficacy will be required to determine if the benefits of therapy are
outweighing the risks associated with the controlled substance. If the patient is
experiencing significant side effects or adverse reactions, including substance misuse,
that outweigh analgesia, the provider should consider discontinuation of the therapy to
ensure patient safety.
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Methods
Setting
The project took place in a primary care practice within the Care New England
Medical Group. The practice focuses on internal medicine and is located in an urban area
with a large patient population. This practice consists of a resident clinic, with first,
second, and third-year resident physicians who rotate through this setting. Each resident
is supervised by an attending physician, and each attending physician is responsible for
supervising five residents per shift. Each provider working in these settings usually
performs visits on eighteen to twenty patients per day. These patients are seen in the
office for a multitude of complex care needs, including managing chronic and acute pain
needs. Patients are all age 18 and older.
Participants
This project involved the education of providers regarding implementation of the
ORT and best practices in the management of patients at risk for opioid use disorder.
Outcomes related to compliance at the patient and provider level, as previously described,
was evaluated by retrospective chart review. Providers who were actively employed by
the specified clinical site were included in the educational intervention. These providers
consist of resident physicians (n = 15) and attending physicians (n = 8). Data related to
patient compliance was collected by retrospective chart review of adult patients receiving
treatment for acute or chronic pain, or who were identified as being at-risk for, or were
receiving treatment for a substance use disorder. No patient identifiers were collected and
data was evaluated at the aggregate level only.
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Intervention
Baseline data was collected by retrospective chart review for a two-month period
prior to the intervention (June to July 2019). The primary investigator (PI) independently
screened all charts at the clinic for the above criteria. Specific data collected included
compliance with ORT implementation, controlled substance agreements, PDMP review,
and number of inappropriate opioid prescriptions. Following collection of baseline data,
the PI delivered an educational program (October 2019) addressing the ORT, ASAM, and
RIDOH guidelines for safe opioid prescribing practices and the potential benefits of
compliance with these measures. The education was delivered in the form of a
PowerPoint presentation and paper handouts were provided to reinforce teaching points.
Education was delivered to providers in half-hour time slots dedicated to the project, as
had been approved by the office manager. The educational sessions occurred during
resident learning times or attending administrative times, thereby reducing the loss of
clinical time. Provider participation was voluntary.
The intervention period continued for three months (October to December 2019),
after which the PI collected post-intervention data for the immediate period following the
intervention. Data was monitored for short-term sustainability of outcomes through May
2020. Appendix A demonstrates the complete timeline for project implementation and
evaluation.
Measures and Analysis
Pre- and post-intervention data was collected by retrospective chart review.
Demographic data was reported using descriptive statistics. Differences between pre- and
post-intervention outcomes was analyzed using Chi-Square. As the project required only
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aggregate level data, no patient identifiers were collected. Goals were to increase
provider compliance with evidence based opioid prescribing practices.
Ethical Considerations
This project was reviewed and approved by both the organizational and
educational setting’s Institutional Review Boards (IRB). Waiver of informed consent was
requested and was granted by the IRB, as this quality improvement project involved the
implementation of established best practices and did not involve risk beyond that
associated with routine practice. Participation in the education sessions was strictly
voluntary and there were no penalties for lack of participation.
Results
Data collected in the post-implementation period demonstrated an increase in
guideline implementation. Urine toxicology monitoring increased from 73.86% to 95.8%
compliance (p = 0.002), PDMP review increased from 42.11% to 62.50% compliance (p
= 0.12), and CSA in place increased from 42.11% to 58.33% compliance (p = 0.13). The
number of cases in which two or more measures were simultaneously implemented rose
from 36.84% to 54.17% (p = 0.10). New opioid prescriptions decreased from 5.26% to
4.17%, meaning less new opioid initiations took place. Because the ORT had not been
implemented prior to the intervention, compliance with this measure was 0% at baseline.
Implementation of the ORT was not achieved during this project with compliance
remaining at 0% after the intervention. Urine toxicology monitoring had a statistically
significant increase from pre- to post-intervention. See Table 1 and Figure 1 below.
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Table 1
Pre and Post-Intervention Data for Guideline Implementation
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Figure 1
Pre and Post Intervention Compliance with Best Practices

Discussion
This quality improvement study was performed to facilitate implementation of
best practice guidelines. Although current guidelines are well established, limited quality
improvement studies exist to inform the effectiveness of interventions to consistently
implement these guidelines in practice. This project demonstrated strong improvements
in all areas, except for the implementation of patient screening utilizing the ORT.
Overall, improvements ranged from 20% to 48%. All improvements were clinically
significant. Although a lack of patient screening using the ORT continued during the
post-intervention period, this did not appear to impact implementation of other practices.
It is unknown if patient screening would have further increased improvements in urine
toxicology screening, PDMP review and implementation of CSAs. Further research is
needed to better understand this relationship. Although clinically significant improvement
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was noted in all areas, the only statistically significant improvement was noted in urine
toxicology screening. However, the sample size for this project was small. Statistical
significance in other areas may have been reached with a larger sample.
Strengths associated with this project included strong support of leadership and
participating providers for project initiation and implementation. There was a measurable
positive provider response to education seen in improvements in guideline
implementation. There was an increased awareness among providers of evidence-based
guidelines and the rationale for consistent implementation. Overall, a clear improvement
in practice was noted in the clinical setting.
Limitations associated with the project included a short implementation time. In
addition, this project was limited to a single setting and had a small sample size. The
education took place in a resident clinic, in which residents were already inundated with
weekly education seminars related to their program. Real-time auditing and feedback was
planned, but was unable to be performed due to time constraints. There was also a lack of
inclusion of ancillary staff in the intervention, which may have further improved urine
toxicology monitoring as medical assistants were primarily responsible for ensuring this
was performed.
Sustainability and Scalability
Sustainability is defined as locking in the progress made by an improvement
initiative and adapting and spreading the initiative to other areas so that the greatest
number of patients will benefit (Moran, Burson, & Conrad, 2020). This is often
accomplished by first disseminating information about successful interventions and
providing evidence that the intervention is worthwhile, beneficial, and cost-effective
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(Moran, Burson, & Conrad, 2020). Sustainability requires obtaining input and buy-in for
continued project support of the initiative from all key stakeholders and decision-makers.
Short- and long-term objectives must be explicitly defined and determined so that a
common goal is shared among all stakeholders (Moran, Burson, & Conrad, 2020).
Resources required for this project included administrative support for provider
participation and time of the investigator devoted to the continuation of the project.
The NHS Sustainability Model and Guide provides a practical resource for
assessing and planning for optimal project sustainability (Maher, Gustafson, & Evans,
2017). The sustainability model consists of ten factors relating to staff, processes, and
organizational issues (Maher, Gustafson, & Evans, 2017). This model was used to
identify strengths and weaknesses during the planning phases of this project so that
appropriate strategies could be implemented to optimize the chances of sustainability of
the project. Sustainability was reassessed upon completion of the project (see Appendix
D).
Conclusion
This project introduced evidence-based practice guidelines into a clinical setting
where compliance was poor and measures were under-utilized. The intervention led to
improved outcomes related to compliance with best practices in opioid prescribing. There
is a need for ongoing work to adapt and scale this quality improvement project across
multiple practices within this and other healthcare settings. There is a need for continued
education for providers and members of the multi-disciplinary team to ensure
sustainability of this intervention. There is also a need to educate patients and the
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community about the rationale for these guidelines and benefits associated with
implementation.
Future research should be performed to determine the relationship between risk
assessment and screenings with regards to guideline implementation. The impact of
including office staff in the education sessions, as well as the impact of implementing
real-time auditing and feedback throughout the project, should be further explored in
future studies. Future practice scholarship should also be targeted at improving long-term
outcomes, including reductions in mortality and morbidity related to opioid use disorders.
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Appendices
Appendix A
Figure 1: Timeline/PERT Chart

Development of Project
Proposal (Aug 2019)

Real-Time Auditing
and Feedback with
use of PDSA Cycles
(Sept to Dec 2019)

Aug

Sept

Oct

Nov

IRB Approval
(Sept 2019)

Retrospective
Data Collection
from June to
Aug (Sept 2019)

Implementation
of Educational
Program (Sept
2019)

Data Analysis and
Dissemination (Jan to
May 2020)

Dec

Jan

Feb

Retrospective Collection
of Post-Intervention Data
from Oct to Dec (Jan
2020)

Mar

Apr

May
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Appendix B
Table 1: Cost-Benefit Analysis

Costs Associated with Project
Category
Paper Materials
- Paper handouts
- Printing expenses
- Copying expenses

Travel Expenses

Time

Details
Paper supplies, printing
costs, and copying
expenses will need to be
considered in order to
provide providers with
handouts related to the
subject material
Gas utilized for the travel
time of the primary
investigator between
clinical site locations
Time will be required by
the primary investigator to
create the educational
materials, as well as
clinical site providers will
need to utilize
administrative time to
attend sessions

Cost in 1 year
$20-$30

$20-40

Sessions will be held
during pre-scheduled
administrative times so
clinical time will not be
utilized. Productivity is not
expected to decrease
during educational
sessions.

Benefits Associated with Project
Benefit
Increased provider knowledge of
nationally recognized guidelines to
manage controlled substances
Increased integration and compliance with
guidelines
Decreased inappropriate opioid initiations
and generalized reduction in publicly
circulating opioids
Decrease incidence of OUD and overdose

Benefits within 12 Months
Utilization of tools will increase provider
cognizance of individual patient risk and
positively impact treatment decisions
Compliance with mandatory guidelines
improves quality of care
Improves patient and public safety with
decreased access to controlled substances
Increases patient safety, decreases
potentially life-threatening emergencies
related to opioid use
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Appendix C
Table 2: Force-Field Analysis

34

Appendix D
Table 3: Sustainability Assessment
Modified from the NHS Sustainability Model and Guide (Maher, Gustafson, & Evans,
2017)

Process
Factor
Benefits beyond
helping patients

Score
8.5

Credibility of the
benefits

9.1

Adaptability of
improved process

3.4

Effectiveness of the
system to monitor
progress

3.3

Description
We can demonstrate that
the change has a wide range
of benefits beyond helping
patients, for example, by
reducing waste, creating
efficiency, or making
people’s jobs easier
Benefits of the change are
widely communicated,
immediately obvious,
supported by evidence, and
believed by stakeholders.
Staff is fully able to
describe a wide range of
intended benefits for this
initiative.
The improved process can
be adapted to support wider
organizational change but it
would be disrupted if
specific individuals or
groups left the project.
Elements of this work will
continue to meet our
organization’s
improvement needs.
There is a system in place
to provide evidence of
impact, including benefits
analysis, monitor progress,
and communicate the
results. This is not set up to
continue beyond the formal
life of the project.

Evaluation
Development of an
ORT score for easy
clinical utilization

Notable increase in
clinical guideline
use with increased
staff support for
implementation

Will need sustained
efforts to continue
utilization in clinical
practice. Will benefit
from spread to other
clinical sites within
the practice setting.

Will require a
monitor moving
forward to continue
chart assessment for
utilization

Staff
Staff involvement and
training to sustain the
process

4.9

Staff have not been
involved from the
beginning of the change,

Education provided
helped staff
understand utility
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Staff behaviors
towards sustaining the
change

11.0

Senior leadership
engagement and
support

15.0

Clinical leadership
engagement and
support

15.0

Fit with the
organization’s
strategic aims and
culture

7.0

but they have received
training in the new way of
working
Staff is able to share their
ideas regularly and some of
them have been taken on
board during the project.
They believe that the
change is a better way of
doing things and have been
empowered to run small
scale test cycles (PDSA)
Organizational leaders are
highly involved and visible
in their support of the
change process. They use
their influence to
communicate the impact of
the work and to break down
any barriers. Staff regularly
shares information with and
actively seek advice from
leaders.
Clinical leaders are highly
involved and visible in their
support of the change
process. They use their
influence to communicate
the impact of the work and
to break down any barriers.
Staff regularly shares
information with and
actively seek advice from
clinical leaders.

and importance of
guideline
implementation
Staff will engage in
future research to
support consistent
utilization

Senior leadership
will continue to
support staff efforts
to continue research
in this area

Clinical leaders will
collaborate with
staff for further
implementation
strategies and
education
incorporation

Organization
The goals of the change are
clear and have been widely
spread. They are consistent
with and support the
organization’s strategic
aims for improvement. The
organization has
demonstrated successful
sustainability of
improvements before and
has a “can do” culture.

There is a
measurable change
in patient and
provider outcomes
that will support the
overall goals of the
organization
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Infrastructure

4.4

Staff is confident and
This author will
trained in the new way of
continue to help staff
working. However, job
navigate clinical
descriptions, policies, and
guidelines
procedures do not yet
reflect the new process.
Some communication
systems are in place.
Facilities and equipment
are all appropriate to
sustain the new process.
Process Total (24.3) + Staff Total (45.9) + Organization Total (11.4) =
Sustainability Score (81.6)
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Appendix E
Table 4: Opioid Risk Tool (ORT) Sample
Mark each box that
applies
Family history of substance abuse
Alcohol
Illegal Drugs
Rx Drugs
Personal history of substance abuse
Alcohol
Illegal drugs
Rx drugs
Age between 16-45 years
History of preadolescent
sexual abuse
Psychological disease
ADD, OCD, bipolar,
schizophrenia
Depression
Scoring Totals

Female

Male

1
2
4

3
3
4

3
4
5
1
3

3
4
5
1
0

2

2

1

1

Key:
Score of 3 or lower à low risk for future opioid abuse
Score of 4 to 7 à moderate risk for future opioid abuse
F for future opioid abuse
Score of 8 or higherAppendix
à high risk

(Webster & Webster, 2006)

